Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3

Status

Unknown 1Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × CYC065 × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05168904 2024-02-08

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Suspended
210 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT04983810 2024-01-25

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Unknown
330 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡